
Chu-Ya (Jennifer) Yang
Director, External Innovation Partnering at Johnson & Johnson Innovation Asia Pacific @ Johnson & Johnson
About
An experienced scientist, engineer, technology scout, and senior investment analyst with a curious nature, broad functional expertise, and a can-do attitude. Comprehensive knowledge and professional experiences in life science, pharmaceutical, and semiconductor. Filed 2 international patents and published more than 5 peer-reviewed research articles. Skillful and analytical in sourcing and evaluating potential opportunities in healthcare and deep tech for licensing, co-development or investment with successful track records. Made 3 equity investments and established more than 10 research collaborations and partnerships. Effective in managing interdisciplinary projects and intercultural stakeholders in both academia and industry. Striving for excellence and growth.
-
China
Pharmaceuticals
Project Management, Research and Development (R&D), Technology Scouting, Technology Transfer, Venture Capital, Early-stage Startups, Business Development, Cross-functional Collaborations, Commercialization, Due Diligence, Oncology, Biotechnology, Life Sciences, Medical Devices, Regenerative Medicine, Nanotechnology, Pharmaceutical Industry, Semiconductor Industry, Molecular & Cellular Biology, Drug Discovery
Experience

Director of Graduate Research Innovation Program & Head of Health Technology Commercialization
Singapore, Singapore
The Industry Liaison Office (ILO) is the technology translation and commercialization arm of the National University of Singapore (NUS). The Graduate Research Innovation Program (GRIP) is the Industry Liaison Office's flagship program of deep tech venture creation. The program provides step-by-step guidance to NUS postgraduate students and researchers to cultivate deep tech entrepreneurs to transform the university's world-class research into their own deep technology start-ups.

Business Consultant
Wuhan, Hubei, China
iRegene Therapeutics was founded in 2017 by a group of brilliant scientists returning from UK to Wuhan, China. The company aims to develop novel therapeutic approaches to solve unmet medical needs. It focuses on the new generation of chemically defined cell therapy with a chemical induce system that enables easy generation of human cell types with high purity. iRegene's lead program is entering phase I clinical trial for Parkinson's disease.
Chu-Ya (Jennifer) Yang's Contact Information
Phone
Find the Right Leads
Find Verified Contact Data
What LeadContact does well
Find verified emails, phone numbers, and decision-makers with 98% accuracy.
Find Leads
Find the right people by company, role, industry, location, and more.
925M+ professional profiles

Find Emails
Access verified email addresses for your target contacts.
657M+ emails

Find Phone Numbers
Get cross-validated phone data from multiple top sources.
239M+ phone numbers

More Accurate. Lower Cost.
Find contact data in 1 tool with 98% accuracy
LeadContact integrates leading enrichment tools to deliver more accurate contact data—without paying for each one.
Great conversations start with the right contact.
It’s time to find yours.










